Cookies disclaimer

I agree Our site saves small pieces of text information (cookies) on your device in order to deliver better content and for statistical purposes. You can disable the usage of cookies by changing the settings of your browser. By browsing our website without changing the browser settings you grant us permission to store that information on your device.

Lipoprotein Deficient Serum, bovine, BT-907 - LPDS - Bovine Serum, lipoprotein deficient - J65182 - Alfa Aesar

J65182 Lipoprotein Deficient Serum, bovine, BT-907

CAS-Nummer
Synonyme
LPDS
Bovine Serum, lipoprotein deficient

Größe Preis ($) Menge Verfügbarkeit
2x25ml 315,00
25ml Preis auf Anfrage. Klicken Sie auf Zur Angebotsanfrage hinzufügen und wählen Sie die Packungsgröße
Zum Warenkorb hinzufügen Zur Angebotsanfrage hinzufügen Artikel anzeigen

Lipoprotein Deficient Serum, bovine, BT-907

Chemische Eigenschaften

Form
Liquid

Anwendungen

Each lot is evaluated in culture with our LDLs to determine the degree of up regulation of LDL receptors. Lipoprotein Deficient Serum, bovine is used for blocking of interfering antibodies. It is evaluated in conjunction with low-density lipoprotein (LDL) to determine the degree of up regulation of low-density lipoprotein receptors.

The absence of lipoproteins allows for the undertaking of binding studies of lipoproteins to cells without the interference of the endogenous lipoproteins.

Bemerkungen

Prepared from calf serum. Store frozen (-20° C). Stable for 6-12 months if frozen.

The sequential centrifugation used to produce this human lipoprotein deficient serum removes 99% of the circulating lipoproteins (chylomicrons, VLDL, IDL, LDL HDL) and their associated lipids. What remains in the LPDS is mainly fatty acids bound to proteins such as albumin.

This product is virtually lipoprotein free but not totally lipid free due to the presence of mainly the non-lipoprotein associated fatty acids. There may also be a very small of amount of sterols such as cholesterol bound to some proteins as well.

If there is a need for lipid free serum, then there are multiple protocols in the literature for the production of lipid free serum by the use of organic solvent extraction. Most of those protocols remove 97-99% of the cholesterol, triglycerides, and free fatty acids.

Literaturverweise

Salminen, A.; Åström, P.; Metso, J.; Soliymani, R.; Salo, T.; Jauhiainen, M.; Pussinen, P. J.; Sorsa, T. Matrix metalloproteinase 8 degrades apolipoprotein A-I and reduces its cholesterol efflux capacity. FASEB J. 2015, 29 (4), 1435-1445.

Romagnuolo, R.; Scipione, C. A.; Boffa, M. B.; Marcovina, S. M.; Seidah, N. G.; Koschinsky, M. L. Lipoprotein(a) Catabolism Is Regulated by Proprotein Convertase Subtilisin/Kexin Type 9 through the Low Density Lipoprotein Receptor. J. Biol. Chem. 2015, 290 (18), 11649-11662.

Weitere Referenzen

Harmonized Tariff Code
3002.19
TSCA
No

Empfohlen

  • 11828

    Tungsten(VI) oxide, 99.8% (metals basis)
  • L19347

    Dibenzyl azodicarboxylate, 96%
  • H27120

    3-Hydroxy-2',4',7-trimethoxyflavone, 97%
  • J66526

    Thrombin Receptor Activator Peptide 6
  • 13850

    Vanadium, plasma standard solution, Specpure®, V 1000µg/ml

Kürzlich angesehen

Chemikalien

Life science

Metalle und Stoffe

Katalysatoren

Forschungs- und Laborbedarf